Slide 1: Thyrocare – Letter to Stock Exchanges on Quarterly Results
Thyrocare’ The Trust. The Truth. November 15, 2021 The National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Dear Sirs, The Bombay Stock Exchange Ltd Phiroze Jeejeeboy Towers Dalal Street, Mumbai- 400 001 Sub: Presentation on Quarterly Results for
Slide 2: Quarterly Presentation – September 2021
Thyrocare Technologies Limited Quarterly Presentation – September 2021
Slide 3: Disclaimer
Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informatio
Slide 4: Key Highlights - Pathology
Key Highlights - Pathology Revenue from operations of Rs. 169 Crore, primarily consists of Revenue from Covid of Rs. 69 Crore, mainly from Government contracts. Revenue for half year ended 30 September 2021 of Rs. 328 Crore grew by 62 % YOY, this Revenue QoQ 6% ↑ despite reduced realization per test
Slide 5: Highest Revenue clocked in Q2FY22, mainly driven by the B2G Business
Highest Revenue clocked in Q2FY22, mainly driven by the B2G Business 66.2% Revenue by sales channel (B2B,B2C and B2G) – INR Cr, % • Company clocked highest sales in Q2. Pathology 313 segment revenue crossed INR 300 cr. In half year. 18.0% • B2B, B2C & B2G mix has 43.3% 93 changed in Q2. B2B business
Slide 6: A surge in patients witnessed due to high volumes of business coming from NHM Maharashtra
A surge in patients witnessed due to high volumes of business coming from NHM Maharashtra Patient count by sales channel (B2B,B2C and B2G) – Lacs, % B2G • The volume growth has B2C exceeded revenue growth B2B 500 401 due to a steep reduction in 387 Rev/Patient 353 355 COVID prices over the last 323
Slide 7: Significant uptick is observed in Covid business due to second wave
Significant uptick is observed in Covid business due to second wave Revenue by Test Type (NOVID vs COVID) – INR Cr, % 66.2% Infectious Covid 18 • Covid revenue increased Non Covid sequentially in Q2 on account of bulk business coming from B2G vertical 18.0% - 0 3 • Covid however is expected 121 to t
Slide 8: Consistent surge in per patient revenue post-covid
Consistent surge in per patient revenue post-covid due to increase revenue share of Covid and preventive care business Patient count by Test Type (NOVID vs COVID) – Lacs, % Infectious Covid Non Covid 325 327 326 • Growth in patient count is Rev per Patient (NOVID) 272 not significant, however 252 24
Slide 9: Preventive care business is on the growth trajectory after pandemic de-growth
Preventive care business is on the growth trajectory after witnessing a significant de-growth due to pandemic Revenue by Test Type (Aarogyam vs Others) – INR Cr, % 66.2% • Growth in Aarogyam in Q2 is mainly from B2C channel driven by D2C and Camps. • Contribution of Others 18.0% Aarogyam within Non
Slide 10: Income Statement - Pathology
Income Statement - Pathology Revenue from operations of Rs. 169 Crore, primarily consists of Revenue from Covid of Rs. 69 Crore, mainly from Government contracts. Revenue for half year ended 30 September 2021 of Rs. 328 Crore grew by 62 % YOY, this despite reduced realization per test for Covid RTPC
Slide 11: Revenue - source
Revenue - source Total Revenue (in crore) Q-Sep20 Q-Jun21 Q-Sep21 Diagnostic services (in crore) 148.54 159.26 168.75 Sale of goods (in crore) Q-Sep20 Q-Jun21 Q-Sep21 Q-Sep20 Q-Jun21 Q-Sep21 145.01 152.84 164.94 3.53 6.42 3.81 98% 96% 98% B2B B2G B2C 2% 4% 2% Sep20 Jun21 Sep21 Sep20 Jun21 Sep21 Sep2
Slide 12: Income Statement - Radiology
Income Statement - Radiology Radiology business accounted for 4% of reported consolidated revenue of Thyrocare Group in current quarter. Significant revival in PETCT revenue in second quarter is evidenced after subsiding of the 2nd wave. Patient footfall increased across the centres in the second qu
Slide 13: Radiology revival after subsiding of the 2nd wave
Significant revival is evidenced after subsiding of the 2nd wave. Patient footfall increased across the centres in the second quarter. Revenue Radiology by sales channel (Owned/ Partnered) – INR Cr, % Partnered Owned -27 % 7.30 - 46% 67.5% 4.18 3.12 4.72 8.91 2.99 5.22 3.69 4.30 4.41 … 0.04 1.11 1.1
Slide 14: Thank You
Thank You